|
Volumn 21, Issue 24, 2003, Pages 3465-3467
|
Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women
|
Author keywords
Breast milk; Lower respiratory tract; Respiratory syncytial virus
|
Indexed keywords
CYTOKINE;
HYBRID PROTEIN;
IMMUNOGLOBULIN A ANTIBODY;
IMMUNOGLOBULIN G ANTIBODY;
MATERNAL ANTIBODY;
NEUTRALIZING ANTIBODY;
PLACEBO;
RESPIRATORY SYNCYTIAL VIRUS VACCINE;
BREAST MILK;
CHILD DEVELOPMENT;
CHILD GROWTH;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOUBLE BLIND PROCEDURE;
DRUG SAFETY;
DRUG TOLERABILITY;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FEMALE;
FEVER;
GEOMETRY;
HALF LIFE TIME;
HUMAN;
IMMUNIZATION;
IMMUNOGENICITY;
INFANT;
INJECTION SITE;
MORBIDITY;
NORMAL HUMAN;
OUTCOMES RESEARCH;
PAIN;
PREGNANCY;
PRIORITY JOURNAL;
PROGENY;
RANDOMIZED CONTROLLED TRIAL;
RESPIRATORY SYNCYTIAL PNEUMOVIRUS;
RESPIRATORY TRACT DISEASE;
SIDE EFFECT;
T LYMPHOCYTE ACTIVATION;
THIRD TRIMESTER PREGNANCY;
VIRUS INFECTION;
WESTERN BLOTTING;
|
EID: 0038384095
PISSN: 0264410X
EISSN: None
Source Type: Journal
DOI: 10.1016/S0264-410X(03)00352-9 Document Type: Conference Paper |
Times cited : (194)
|
References (4)
|